Please login to the form below

Not currently logged in
Email:
Password:

Zealand adds two observers to board of directors

Martin Nicklasson and Catherine Moukheibir join the firm
Martin Nicklasson

Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company's board of directors in the role of observers.

The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.

Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.

Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand's growth strategy as a maturing biotech company.”

12th November 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

World Mental Health Day 2019: Employment and Mental Illness
Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2019....
Changing direction
Changing direction: adapting to a rapidly-evolving environment
Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace...
customer journey
Understanding the patient journey
What we can learn from customer service...

Infographics